Jkj, in the ASSURE/SUSTAIN combined trials after 6 months within patients with CVD, DM and low HDL 21% of the patients in the conrol group (statin only) had a MACE event (5 pt) after 6 months. In the treated group (rvx-208 + rosuvastatin) only about 5% had a MACE event after 6 months. So the absolute risk reduction was 16% points =21% - 5%. The relative risk reduction was 16%/21% = 76.2%. I used approximate #s but with actuals it was 77%.

Hope that helps.

Toinv